STOCK TITAN

Capricor Therapeutics Inc - $CAPR STOCK NEWS

Welcome to our dedicated page for Capricor Therapeutics news (Ticker: $CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Capricor Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Capricor Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.64%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
clinical trial covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.34%
Tags
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

CAPR Stock Data

172.32M
26.04M
8.2%
21.62%
11.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BEVERLY HILLS

About CAPR

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has